Last reviewed · How we verify

IBI308\cisplatin\gemcitabine

Innovent Biologics (Suzhou) Co. Ltd. · Phase 1 active Small molecule

IBI308\cisplatin\gemcitabine is a Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd.. It is currently in Phase 1 development.

At a glance

Generic nameIBI308\cisplatin\gemcitabine
SponsorInnovent Biologics (Suzhou) Co. Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IBI308\cisplatin\gemcitabine

What is IBI308\cisplatin\gemcitabine?

IBI308\cisplatin\gemcitabine is a Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd..

Who makes IBI308\cisplatin\gemcitabine?

IBI308\cisplatin\gemcitabine is developed by Innovent Biologics (Suzhou) Co. Ltd. (see full Innovent Biologics (Suzhou) Co. Ltd. pipeline at /company/innovent-biologics-suzhou-co-ltd).

What development phase is IBI308\cisplatin\gemcitabine in?

IBI308\cisplatin\gemcitabine is in Phase 1.

Related